MEI Pharma ( MEI Pharma )

MEI Pharma

MEI Pharma's picture

About MEI Pharma

MEI Pharma (formerly Marshall Edwards Inc.) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and two isoflavone-based drug candidates, ME-143 and ME-344.

MEI Pharma press release, blog etc

10/11/2018 - 18:32 MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
06/30/2018 - 07:37 MEI Pharma Reports Fiscal Year 2018 Results and Operational Highlights
06/04/2018 - 10:50 MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
05/31/2018 - 13:02 MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients
05/16/2018 - 18:06 MEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
05/14/2018 - 06:40 MEI Pharma Announces $75 Million Private Placement
01/11/2018 - 01:58 Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)
12/21/2017 - 08:01 MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
11/07/2017 - 03:55 MEI Pharma to Present at Stifel 2017 Healthcare Conference
09/05/2017 - 15:17 MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
09/05/2017 - 08:43 MEI Pharma Reports Fiscal Year 2017 Results
08/31/2017 - 04:45 MEI Pharma to Present at Two Upcoming Investor Conferences
08/29/2017 - 07:52 MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017
08/02/2017 - 05:17 Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
06/14/2017 - 07:08 Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
06/05/2017 - 05:52 Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
05/31/2017 - 08:41 MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma
05/18/2017 - 08:37 Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia